(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 19.44% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Alvotech's revenue in 2026 is $562,043,000.On average, 8 Wall Street analysts forecast ALVO's revenue for 2026 to be $207,154,204,225, with the lowest ALVO revenue forecast at $183,546,060,432, and the highest ALVO revenue forecast at $223,795,089,398. On average, 8 Wall Street analysts forecast ALVO's revenue for 2027 to be $243,697,975,135, with the lowest ALVO revenue forecast at $205,877,497,785, and the highest ALVO revenue forecast at $296,199,015,788.
In 2028, ALVO is forecast to generate $303,256,798,826 in revenue, with the lowest revenue forecast at $242,280,799,770 and the highest revenue forecast at $357,727,525,944.